Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Rating of “Buy” from Brokerages

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) have earned an average rating of “Buy” from the fifteen analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $110.6154.

A number of equities analysts recently weighed in on SLNO shares. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a report on Monday, January 12th. The Goldman Sachs Group set a $125.00 price target on shares of Soleno Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 7th. Zacks Research raised shares of Soleno Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. HC Wainwright restated a “buy” rating and issued a $120.00 price objective (up from $110.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Finally, Robert W. Baird set a $107.00 target price on shares of Soleno Therapeutics in a report on Tuesday, January 13th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Pictet Asset Management Holding SA lifted its stake in shares of Soleno Therapeutics by 13.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 624,128 shares of the company’s stock valued at $28,897,000 after acquiring an additional 73,504 shares during the last quarter. UBS Group AG increased its stake in Soleno Therapeutics by 7.1% in the 4th quarter. UBS Group AG now owns 169,506 shares of the company’s stock worth $7,848,000 after purchasing an additional 11,198 shares during the period. Teachers Retirement System of The State of Kentucky increased its stake in Soleno Therapeutics by 50.6% in the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 20,941 shares of the company’s stock worth $970,000 after purchasing an additional 7,040 shares during the period. Vanguard Group Inc. lifted its position in Soleno Therapeutics by 9.0% in the fourth quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock valued at $141,695,000 after purchasing an additional 253,212 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in Soleno Therapeutics by 8.1% in the fourth quarter. Arizona State Retirement System now owns 12,629 shares of the company’s stock valued at $585,000 after purchasing an additional 948 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Stock Performance

NASDAQ SLNO opened at $40.55 on Friday. Soleno Therapeutics has a 52-week low of $39.43 and a 52-week high of $90.32. The company has a fifty day moving average of $46.71 and a 200-day moving average of $60.11. The company has a market capitalization of $2.18 billion, a P/E ratio of -22.04 and a beta of -3.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.88 and a current ratio of 16.08.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million. As a group, equities research analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.